Novartis Japan Girds For Imminent Business Suspension
This article was originally published in PharmAsia News
Executive Summary
Novartis's Japanese subsidiary must suspend the bulk of its business activities for 15 days this month following the confirmation of an expected official order in relation to the firm's tardy reporting of side-effects.